• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

9. 血糖治疗的药理学方法:2025年糖尿病护理标准

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.

出版信息

Diabetes Care. 2025 Jan 1;48(Supplement_1):S181-S206. doi: 10.2337/dc25-S009.

DOI:10.2337/dc25-S009
PMID:39651989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11635045/
Abstract

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

摘要

美国糖尿病协会(ADA)的《糖尿病诊疗标准》包含了ADA当前的临床实践建议,旨在提供糖尿病护理的组成部分、一般治疗目标和指南,以及评估护理质量的工具。ADA专业实践委员会是一个跨专业专家委员会,其成员负责每年更新《诊疗标准》,如有必要可更频繁更新。有关ADA标准、声明和报告的详细说明,以及ADA临床实践建议的证据分级系统和专业实践委员会成员完整名单,请参阅“引言和方法”。欢迎希望对《诊疗标准》发表评论的读者访问professional.diabetes.org/SOC进行评论。

相似文献

1
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.9. 血糖治疗的药理学方法:2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S181-S206. doi: 10.2337/dc25-S009.
2
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025.6. 血糖目标与低血糖:2025年糖尿病照护标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S128-S145. doi: 10.2337/dc25-S006.
3
17. Diabetes Advocacy: Standards of Care in Diabetes-2025.17. 糖尿病倡导:2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S335-S336. doi: 10.2337/dc25-S017.
4
16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2025.16. 医院中的糖尿病护理:2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S321-S334. doi: 10.2337/dc25-S016.
5
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025.2. 糖尿病的诊断与分类:《2025年糖尿病防治标准》
Diabetes Care. 2025 Jan 1;48(Supplement_1):S27-S49. doi: 10.2337/dc25-S002.
6
7. Diabetes Technology: Standards of Care in Diabetes-2025.7. 糖尿病技术:2025年糖尿病照护标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S146-S166. doi: 10.2337/dc25-S007.
7
14. Children and Adolescents: Standards of Care in Diabetes-2025.14. 儿童和青少年:2025年糖尿病照护标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S283-S305. doi: 10.2337/dc25-S014.
8
13. Older Adults: Standards of Care in Diabetes-2025.13. 老年人:2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S266-S282. doi: 10.2337/dc25-S013.
9
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2025.15. 妊娠期糖尿病的管理:2025年糖尿病诊疗标准。
Diabetes Care. 2025 Jan 1;48(Supplement_1):S306-S320. doi: 10.2337/dc25-S015.
10
1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2025.1. 改善人群护理与促进健康:2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S14-S26. doi: 10.2337/dc25-S001.

引用本文的文献

1
Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.沙特阿拉伯社区药剂师在胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂方面的知识、咨询实践、感知障碍及临床决策
Diabetes Metab Syndr Obes. 2025 Aug 30;18:3093-3107. doi: 10.2147/DMSO.S552287. eCollection 2025.
2
Incretin-Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists.基于肠促胰岛素的背景胰岛素治疗辅助手段用于管理 1 型糖尿病患者的超重体重:来自意大利临床内分泌学家协会的专家意见观点
Diabetes Metab Res Rev. 2025 Sep;41(6):e70073. doi: 10.1002/dmrr.70073.
3
Metformin-Associated Lactic Acidosis (MALA): When a Common Drug Turns Catastrophic.二甲双胍相关性乳酸性酸中毒(MALA):一种常用药物何时会引发灾难性后果。
Cureus. 2025 Aug 3;17(8):e89292. doi: 10.7759/cureus.89292. eCollection 2025 Aug.
4
Enhancing resistance training adherence in older adults with sarcopenia or osteoporosis: a study on referral success rates.提高患有肌肉减少症或骨质疏松症的老年人对阻力训练的依从性:一项关于转诊成功率的研究。
Front Public Health. 2025 Aug 18;13:1632960. doi: 10.3389/fpubh.2025.1632960. eCollection 2025.
5
Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease.对胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂作为阿尔茨海默病潜在治疗方法的真实世界观察。
Alzheimers Dement. 2025 Sep;21(9):e70639. doi: 10.1002/alz.70639.
6
The Relationship Between Gestational Diabetes, Emotional Eating, and Clinical Indicators.妊娠期糖尿病、情绪化进食与临床指标之间的关系
Medicina (Kaunas). 2025 Aug 12;61(8):1447. doi: 10.3390/medicina61081447.
7
Exploring Combined Use of Continuous Glucose Monitoring and Anti-Diabetes Medications on Glycaemic Control for People With Type 2 Diabetes Not Using Insulin.探索持续葡萄糖监测与抗糖尿病药物联合使用对未使用胰岛素的2型糖尿病患者血糖控制的影响
Endocrinol Diabetes Metab. 2025 Sep;8(5):e70089. doi: 10.1002/edm2.70089.
8
Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations.基于孟德尔随机化研究及欧洲人群系统评价探究胰高血糖素样肽-1受体激动剂引发糖尿病视网膜病变的风险
Diabetol Metab Syndr. 2025 Aug 20;17(1):345. doi: 10.1186/s13098-025-01878-3.
9
Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes.2型糖尿病患者转换为使用德谷胰岛素/门冬胰岛素笔芯可重复使用笔芯的实际效果。
Diabetol Metab Syndr. 2025 Aug 19;17(1):342. doi: 10.1186/s13098-025-01918-y.
10
Continuous Glucose Monitoring-Enhanced eConsult Improves Clinical Outcomes in Adults Living With Diabetes in a Safety Net Primary Care Setting.持续葡萄糖监测强化电子咨询改善安全网初级保健环境中糖尿病成年患者的临床结局。
J Diabetes Res. 2025 Aug 5;2025:5547910. doi: 10.1155/jdr/5547910. eCollection 2025.

本文引用的文献

1
Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association.复合胰高血糖素样肽-1及双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂:美国糖尿病协会声明
Diabetes Care. 2025 Feb 1;48(2):177-181. doi: 10.2337/dci24-0091.
2
Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases.非处方在线购买司美格鲁肽的安全性与风险评估
JAMA Netw Open. 2024 Aug 1;7(8):e2428280. doi: 10.1001/jamanetworkopen.2024.28280.
3
Effectiveness of shared decision-making for glycaemic control among type 2 diabetes mellitus adult patients: A systematic review and meta-analysis.共享决策对 2 型糖尿病成年患者血糖控制效果的系统评价和 Meta 分析。
PLoS One. 2024 Jul 31;19(7):e0306296. doi: 10.1371/journal.pone.0306296. eCollection 2024.
4
Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.成人糖尿病高血糖危象:共识报告。
Diabetes Care. 2024 Aug 1;47(8):1257-1275. doi: 10.2337/dci24-0032.
5
Effect of metformin (vs. placebo or sulfonylurea) on all-cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta-analysis.二甲双胍(与安慰剂或磺脲类药物相比)对糖尿病患者全因死亡率、心血管死亡率及心血管事件发生率的影响:一项包含荟萃分析的系统评价的伞状综述
J Diabetes Metab Disord. 2023 Oct 11;23(1):27-38. doi: 10.1007/s40200-023-01309-y. eCollection 2024 Jun.
6
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.替尔泊肽治疗代谢相关脂肪性肝炎伴肝纤维化
N Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8.
7
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk.降糖药物对中度心血管风险的2型糖尿病患者心血管结局的有效性。
Nat Cardiovasc Res. 2024 Apr;3(4):431-440. doi: 10.1038/s44161-024-00453-9. Epub 2024 Apr 3.
8
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
9
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).一项2型糖尿病强化血糖控制随机对照试验的试验后监测,时间从10年延长至24年(英国前瞻性糖尿病研究91)
Lancet. 2024 Jul 13;404(10448):145-155. doi: 10.1016/S0140-6736(24)00537-3. Epub 2024 May 18.
10
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.替尔泊肽在超重和肥胖 1 型糖尿病成人患者中的疗效和安全性。
Diabetes Technol Ther. 2024 Jun;26(6):367-374. doi: 10.1089/dia.2024.0050. Epub 2024 Apr 18.